安杰思上市以来首次净利下滑，股东去年曾多次减持

Core Viewpoint - Antili reported a decline in revenue and net profit for the year 2025, marking the first year-on-year decrease in net profit since its listing in 2023 [1][3]. Financial Performance - The total operating revenue for 2025 was 597.21 million yuan, a decrease of 6.19% compared to the previous year [1][2]. - The net profit attributable to the parent company was 222.82 million yuan, down 24.06% year-on-year [1][2]. - The net profit after deducting non-recurring gains and losses was 191.42 million yuan, reflecting a decline of 29.81% from the previous year [1][2]. - Basic earnings per share were 2.77 yuan, a decrease of 23.90% compared to the previous year [2]. - The weighted average return on net assets was 9.08%, down 3.72 percentage points from the previous year [2]. Asset and Equity Growth - As of the end of the reporting period, total assets amounted to 2,674.01 million yuan, an increase of 4.87% from the beginning of the period [3]. - The equity attributable to the parent company was 2,515.85 million yuan, up 4.95% from the beginning of the period [3]. Shareholder Actions - In 2025, there were multiple instances of shareholder reductions, including a significant "clearing-style" reduction by shareholder Tiantang Silicon Valley [3]. - On May 13, 2025, Tiantang Silicon Valley reduced its holdings by 1,214,483 shares, accounting for 1.4998% of the total share capital [3]. - On September 11, 2025, Tiantang Silicon Valley further reduced its holdings by a total of 1,622,700 shares, representing 2.0039% of the total share capital [3]. - On October 23, 2025, shareholder Xinjian Yuan reduced its holdings by 345,816 shares, accounting for 0.4270% of the total share capital [4]. Company Overview - Antili, established in 2010, focuses on the design and development of products and surgical solutions in the field of minimally invasive interventional therapy, operating as a national high-tech enterprise [4].